Filings

7 documents · 78 matches

1. CLYM Climb Bio, Inc. 10-Q 2025-05-14

   Item 1A. Risk Factors.

   tariff on Canada and Mexico for goods not covered by the United States-Mexico-Canada Agreement (USMCA), and tariffs equaling
   11 matches in this document Show context Copy citation

2. CLYM Climb Bio, Inc. 10-Q 2025-08-12

   Item 1A. Risk Factors.

   tariff of 10% on all U.S. trading partners effective April 5, 2025, and higher individualized reciprocal tariffs on 57 countries
   12 matches in this document Show context Copy citation

3. CLYM Climb Bio, Inc. 10-Q 2025-11-06

   Item 1A. Risk Factors.

   tariff of 10% on all U.S. trading partners effective April 5, 2025, and higher individualized reciprocal tariffs on 57 countries
   12 matches in this document Show context Copy citation

4. CLYM Climb Bio, Inc. 10-Q 2026-08-06

   Item 1A. Risk Factors.

   tariffs on branded or patented pharmaceutical products announcing that the Trump Administration had now “begun preparing” tariffs on manufacturers that
   11 matches in this document Show context Copy citation

5. CLYM Climb Bio, Inc. 10-Q 2026-11-05

   Item 1A. Risk Factors.

   tariff policies or trade restrictions. We cannot yet predict the effect of the recently imposed U.S. tariffs on imports, or the extent
   11 matches in this document Show context Copy citation

6. CLYM Climb Bio, Inc. 10-Q 2026-05-07

   Item 1A. Risk Factors.

   tariff. At the same time, President Trump indicated that these tariffs could be avoided by building pharmaceutical manufacturing facilities in the U.S. Thereafter
   12 matches in this document Show context Copy citation

7. CLYM Climb Bio, Inc. 10-K 2026-03-05

   Item 1A. Risk Factors.

   tariff. At the same time, President Trump indicated that these tariffs could be avoided by building pharmaceutical manufacturing facilities in the U.S. Thereafter
   9 matches in this document Show context Copy citation